Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the country.

The launch incorporates learnings from a (NYSE: HCA), one of the nation's leading healthcare providers. As part of the pilot, ED physicians in four hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits.

“The work we've done on Augmedix Go in the ED demonstrates how the Augmedix team has worked to build a strong, long-term relationship with HCA Healthcare and provide us high-quality, successful deployments,” said Michael J. Schlosser, MD, MBA, FAANS, SVP, Care Transformation and Innovation, HCA Healthcare.

Augmedix Go aims to improve the patient experience at the point of care, increase productivity by improving documentation quality, reduce the cognitive burden of note taking by providers, and shorten chart closure time. The clinician feedback and data garnered from the pilot supported Augmedix Go’s ability to achieve these objectives.

“Using Augmedix allowed me to spend more time with my patients and less time in front of my computer. I was also able to essentially eliminate charting after my shift was over, which makes a huge difference,” said Veronica L. Cassese Klasko, MHSc, MMS, PA-C, physician assistant at HCA Florida Trinity Hospital.

Augmedix’s extensive experience in acute care settings with its other products helped it to fine-tune its AI technology to address the unique challenges of clinical documentation in the ED such as multiple interactions, documenting medical decision making, re-evaluations and progress updates. The workflow in the ED requires technology that can accommodate complex conversations and a plurality of recordings capturing multiple, non-sequential interactions with a single patient. All of which occurs in a typically noisy environment.

Augmedix Go offers clinicians the option to engage with patients in a hands-free environment by pairing the mobile app, stored in their lab coat pocket, with a Bluetooth mic, to seamlessly capture patient conversations. Patients consent to the use of Augmedix at a 99% acceptance rate. Clinicians reported positive feedback on the audio capture, note quality, and AI accuracy, even in these challenging environments.

"Despite how loud it was in the ED, Augmedix got the note content right,” said Michael Borunda, M.D., ED Director at HCA Florida Trinity Hospital. “After careful review, I had no edits and was able to send my note straight to the EHR.”

Augmedix utilizes both proprietary fine-tuned large language models (LLMs) and industry-leading foundational LLMs, including ’s suite of medically-tuned models. These AI models are utilized across different specialties and sections of the note to deliver high quality medical documentation. Augmedix Go’s user interface exposes the principal steps in its note creation process to help instill trust among clinicians.

“The launch of Augmedix Go in the ED represents our unwavering commitment to develop solutions for health systems that improve their workflows. Our agility and flexible architecture, exhibited by our broad product suite and open network platform, help us address the complex and varying needs of clinicians and providers,” said Manny Krakaris, CEO of Augmedix. “We have built a sophisticated platform designed to enable clinicians to be present with their patients while trusting that Augmedix technology is doing administrative work unobtrusively in the background.”

For information about implementing Augmedix Go, email .

About Augmedix

Augmedix (Nasdaq: AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.

The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.

Incorporating data from millions of interactions across all care settings, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes.

Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit .

Forward-Looking Statements

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,” “optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the time savings clinicians will experience with Augmedix Go for EDs; the aim of Augmedix Go for ED to improve the patient experience at the point of care, increase productivity by improving documentation quality, reduce the cognitive burden of note taking by providers, and shorten chart closure time; Augmedix Go for EDs allowing clinicians to save time, focus more on the patient and eliminate charting after a provider’s shift; Augmedix’s experience in acute care settings helping fine-tune its AI technology to address the unique challenges of clinical documentation in the ED; Augmedix’s long-term relationship with HCA Healthcare and its ability to provide high-quality, successful deployments; Augmedix Go’s seamless capture of patient interactions; patients’ 99% acceptance rate; Augmedix’s unwavering commitment to develop solutions for health systems that improve their workflows; and Augmedix’s broad product suite and open network platform, helping it to address the complex and varying needs of clinicians and providers. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2024, as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contact Information

Investors:

Matt Chesler, CFA

FNK IR

646-809-2183

Media:

Kaila Grafeman

Augmedix